Trial Profile
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Advanced breast cancer; Non-Hodgkin's lymphoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- 28 Jan 2023 Planned End Date changed from 7 Oct 2022 to 7 Oct 2023.
- 08 Oct 2021 Planned End Date changed from 1 Nov 2021 to 7 Oct 2022.
- 07 Oct 2021 Planned End Date changed from 1 Oct 2021 to 1 Nov 2021.